Last reviewed 2026-04-23 · How we verify

AGN-210669

AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons.

AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons. Used for Chronic pain (specific indication under investigation in Phase 2).

At a glance

Mechanism of action

TRPV1 is a cation channel expressed on nociceptive nerve fibers that mediates pain sensation, particularly in response to heat, capsaicin, and inflammatory mediators. By blocking TRPV1, AGN-210669 reduces the transmission of pain signals from peripheral tissues to the central nervous system. This mechanism is being explored for chronic pain conditions where TRPV1-mediated signaling contributes to pain pathophysiology.

Approved indications

• Chronic pain (specific indication under investigation in Phase 2)

Common side effects

• Hyperthermia or impaired temperature sensation
• Gastrointestinal effects

Key clinical trials

• Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
• Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma (PHASE1, PHASE2)
• Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AGN-210669 CI brief — competitive landscape report
• AGN-210669 updates RSS · CI watch RSS
• Allergan portfolio CI